Editas Medicine, Inc. - Common Stock (EDIT) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2016 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
EDIT on Nasdaq
Shares outstanding
82,773,190
Price per share
$2.05
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
43,072,975
Total reported value
$149,415,066
% of total 13F portfolios
0%
Share change
+1,741,103
Value change
+$7,922,377
Number of holders
190
Price from insider filings
$2.05
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Editas Medicine, Inc. - Common Stock (EDIT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 7.9% $8,500,807 6,539,082 BlackRock, Inc. 31 Mar 2025

As of 30 Sep 2025, 190 institutional investors reported holding 43,072,975 shares of Editas Medicine, Inc. - Common Stock (EDIT). This represents 52% of the company’s total 82,773,190 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Editas Medicine, Inc. - Common Stock (EDIT) together control 44% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 9.7% 8,019,891 +18% 0% $27,829,022
VANGUARD GROUP INC 8.4% 6,965,618 -2.7% 0% $24,170,694
Nuveen, LLC 2.5% 2,091,636 +120% 0% $7,257,977
GEODE CAPITAL MANAGEMENT, LLC 2.5% 2,040,166 +3.9% 0% $7,081,232
STATE STREET CORP 2.3% 1,925,044 +4.2% 0% $6,679,903
TWO SIGMA INVESTMENTS, LP 1.9% 1,584,155 +63% 0.01% $5,497,018
RENAISSANCE TECHNOLOGIES LLC 1.5% 1,277,400 +44% 0.01% $4,432,578
TWO SIGMA ADVISERS, LP 1.5% 1,205,000 +28% 0.01% $4,181,350
MORGAN STANLEY 1.3% 1,087,907 -23% 0% $3,775,037
BANK OF AMERICA CORP /DE/ 1.2% 1,024,240 -5.1% 0% $3,554,114
DIMENSIONAL FUND ADVISORS LP 1.1% 931,910 -34% 0% $3,233,961
JPMORGAN CHASE & CO 0.99% 820,667 -23% 0% $2,847,715
JACOBS LEVY EQUITY MANAGEMENT, INC 0.97% 800,023 +762% 0.01% $2,776,080
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.97% 799,210 -15% 0% $2,773,259
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.94% 779,955 +11% 0% $2,706,444
AQR CAPITAL MANAGEMENT LLC 0.83% 687,755 -10% 0% $2,386,510
NORTHERN TRUST CORP 0.81% 669,689 +1.4% 0% $2,323,821
STIFEL FINANCIAL CORP 0.7% 580,285 +4.5% 0% $2,013,592
KENNEDY CAPITAL MANAGEMENT LLC 0.68% 565,641 -0.35% 0.04% $1,962,774
JANE STREET GROUP, LLC 0.62% 516,595 +98% 0% $1,792,584
GOLDMAN SACHS GROUP INC 0.55% 458,276 -30% 0% $1,590,217
UBS Group AG 0.51% 422,394 -33% 0% $1,465,707
Walleye Capital LLC 0.48% 393,830 0.01% $1,366,590
CITADEL ADVISORS LLC 0.44% 362,193 -43% 0% $1,256,810
ROYAL BANK OF CANADA 0.43% 358,219 +16% 0% $1,243,000

Institutional Holders of Editas Medicine, Inc. - Common Stock (EDIT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 262,671 $542,430 +$31,866 $2.05 12
2025 Q3 43,072,975 $149,415,066 +$7,922,377 $3.47 190
2025 Q2 41,335,195 $90,959,890 -$2,651,397 $2.20 190
2025 Q1 44,006,194 $51,043,015 -$8,641,680 $1.16 187
2024 Q4 51,033,327 $64,808,360 -$26,987,189 $1.27 197
2024 Q3 55,016,547 $187,692,553 -$7,635,788 $3.41 222
2024 Q2 56,385,944 $263,319,901 -$55,744,641 $4.67 230
2024 Q1 67,934,083 $503,996,329 +$59,173,903 $7.42 222
2023 Q4 76,856 $781,852 +$80,706 $10.13 4
2023 Q3 61,340,932 $478,433,060 -$13,701,635 $7.80 215
2023 Q2 62,247,989 $512,223,893 +$81,074,912 $8.23 228
2023 Q1 52,675,001 $381,882,580 -$12,491,718 $7.25 226
2022 Q4 53,542,039 $474,897,836 +$43,186,174 $8.87 238
2022 Q3 48,224,514 $590,280,539 +$9,038,714 $12.24 236
2022 Q2 47,394,140 $560,219,732 +$5,760,144 $11.83 228
2022 Q1 44,027,301 $836,529,116 -$137,808,901 $19.02 230
2021 Q4 50,932,278 $1,354,907,893 -$59,139,576 $26.55 285
2021 Q3 51,656,247 $2,122,990,294 -$9,815,994 $41.08 305
2021 Q2 52,095,575 $2,960,025,026 -$26,483,308 $56.64 308
2021 Q1 51,529,876 $2,164,185,198 +$4,778,591 $42.00 292
2020 Q4 52,902,003 $3,709,110,111 -$146,377,428 $70.11 298
2020 Q3 55,065,784 $1,544,975,458 +$17,229,403 $28.06 230
2020 Q2 54,049,915 $1,597,291,290 +$264,243,048 $29.58 221
2020 Q1 45,308,106 $898,462,798 -$11,811,503 $19.83 180
2019 Q4 45,730,147 $1,354,044,824 +$25,703,970 $29.61 215
2019 Q3 44,014,211 $1,001,814,759 +$118,506,500 $22.74 175
2019 Q2 38,737,580 $958,274,466 +$75,351,825 $24.74 182
2019 Q1 37,423,603 $914,981,343 +$72,896,728 $24.45 191
2018 Q4 34,372,136 $781,752,934 +$24,537,913 $22.75 183
2018 Q3 32,660,669 $1,039,132,534 +$36,040,461 $31.82 188
2018 Q2 31,926,827 $1,143,151,252 +$39,785,721 $35.83 206
2018 Q1 30,938,966 $1,025,598,195 +$25,005,268 $33.15 189
2017 Q4 30,209,795 $928,645,032 +$79,204,316 $30.73 141
2017 Q3 27,173,892 $652,402,128 +$40,463,462 $24.01 112
2017 Q2 29,203,468 $490,093,264 +$21,137,815 $16.78 107
2017 Q1 27,537,538 $614,414,843 +$120,571,399 $22.32 99
2016 Q4 23,489,820 $381,239,290 +$22,265,666 $16.23 83
2016 Q3 22,214,875 $299,455,288 +$9,009,513 $13.48 70
2016 Q2 17,634,311 $429,193,163 -$15,061,651 $24.40 64
2016 Q1 18,151,358 $625,254,000 +$464,066,183 $34.54 48